logo
logo

Pinetree Therapeutics has raised $47 million in an oversubscribed Series B round to advance next-generation protein degraders in oncology.

Oct 29, 2025•4 days ago

Amount Raised

$47 Million

Round Type

SERIES B

CambridgeBiotechnologyHealth Care

Description

Pinetree Therapeutics has successfully completed an oversubscribed Series B funding round, raising $47 million. The capital will be utilized to advance their next-generation protein degraders aimed at treating oncology patients. This significant investment underscores the growing interest in innovative cancer therapies. The funding round was led by prominent investors in the biotech sector.

Company Information

Company

PineTree Therapeutics

Location

Cambridge, Massachusetts, United States

About

Pinetree Therapeutics, based in Cambridge, MA, is a preclinical-stage biotech company developing next-generation targeted protein degraders (TPDs) to overcome drug resistance and tumor recurrence in oncology, with applications in inflammation and immunology. Its proprietary AbReptor™ platform enables selective degradation of membrane-bound and extracellular proteins, offering a differentiated mechanism of action and durable therapeutic benefit. Pinetree is also advancing trispecific degraders and ADC-integrated platforms, and has entered strategic partnerships, including a licensing agreement with AstraZeneca.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech